Refanezumab
- Product NameRefanezumab
- CAS1233953-61-1
- CBNumberCB58080968
- MW0
- MOL FileMol file
- MSDS FileSDS
Refanezumab Price
| Product number | Packaging | Price | Product description | Buy |
|---|---|---|---|---|
| ChemScene CS-0624069 | 1mg | $520 | Refanezumab 99.9% |
Buy |
| ChemScene CS-0624069 | 5mg | $1625 | Refanezumab 99.9% |
Buy |
| ChemScene CS-0624069 | 10mg | $2600 | Refanezumab 99.9% |
Buy |
| aablocks AA02EO85 | 1mg | $664 | Refanezumab ≥95%(SDS-PAGE&SEC-HPLC) |
Buy |
| aablocks AA02EO85 | 5mg | $1660 | Refanezumab ≥95%(SDS-PAGE&SEC-HPLC) |
Buy |
Refanezumab Chemical Properties,Usage,Production
Uses
Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke[1][2].in vivo
Refanezumab (GSK249320; 10 mg/kg; IV; starting 24 hours post-stroke and continuing weekly for 6 more doses) shows larger increases in neuroscore and staircase test. Refanezumab by intravenous penetrates the lesion site and is associated with a small effect on functional outcomes when initiated 24 hours post-stroke[1].
| Animal Model: | Male Sprague Dawley rats (weight 361g)[1] |
| Dosage: | 10 mg/kg |
| Administration: | IV; starting 24 hours post-stroke and continuing weekly for 6 more doses; starting seven days post-stroke and continuing weekly for 5 more doses |
| Result: | Animals treated 24 hours post-stroke showed larger increases in neuroscore and staircase test as compared to controls, but animals treated 7 days post-stroke showed no significant behavioral benefit. |
References
[1] Diana Cash, et al. GSK249320, A Monoclonal Antibody Against the Axon Outgrowth Inhibition Molecule Myelin-Associated Glycoprotein, Improves Outcome of Rodents with Experimental Stroke. J Neurol Exp Neurosci. 2016;2(2):28-33. Epub 2016 Nov 21. PMID:28018988[2] B Abila, et al. First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers. Clin Pharmacol Ther. 2013 Feb;93(2):163-9. DOI:10.1038/clpt.2012.227
Preparation Products And Raw materials
Refanezumab Suppliers
Global(19)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| 15026964105 | 2881489226@qq.com | China | 87240 | 60 | |
| 177-54423994 17754423994 |
2853530910@QQ.com | China | 7996 | 62 | |
| 15817493340 | 981810490@qq.com | China | 1577 | 58 | |
| 027-65317797 15926423062 |
422450190@qq.com | China | 10302 | 58 | |
| 4008200310 15002144251 |
marketing@tsbiochem.com | China | 24951 | 58 | |
| 027-65279366 18108604356 |
products@biolabreagent.com | China | 9864 | 58 | |
| 13720134139 086-15871494362 13720134139 |
orders@jknbiochem.com | China | 7284 | 58 | |
| 021-65675885 18964387627 |
customer_service@efebio.com | China | 11963 | 58 | |
| 027-027-16602739303 16602739303 |
673003916@qq.com | China | 4622 | 58 | |
| 6206333 13167063860 |
anhua.mao@aladdin-e.com | China | 49394 | 58 |
1233953-61-1, RefanezumabRelated Search
PROMPT×
PROMPT
The WhatsApp is temporarily not supported in mainland China
The WhatsApp is temporarily not supported in mainland China
Cancel
Determine